1. Preface

2. Executive Summary
2.1. LATAM Adalimumab: Market Snapshot
2.2. Comparative Analysis: LATAM Adalimumab Market, by Country, 2014 & 2023 (Value %)
2.3. LATAM Adalimumab Market Revenue, by Application, 2014 (US$ Mn)

3. Industry Analysis: LATAM Adalimumab Market
3.1. Introduction
3.2. Market Drivers
3.2.1. Driver 1: Favorable Local Regulations
3.2.2. Driver 2: Expertise in Biologic Product Research To Support Local And Foreign Investments
3.3. Market Restraints
3.3.1. Restraint 1: High Cost of R&D and Clinical trials
3.3.2. Restraint 2: Lack of reimbursement for biosimilars resulting in high out-of-pocket costs
3.4. Market Opportunities
3.4.1. Opportunity 1: LATAM, an attractive base for the biosimilar developers for their product expansion
3.5. Market Attractiveness Analysis- LATAM Adalimumab Market, by Country (2014) (value %)
3.6. Pipeline Analysis: LATAM Adalimumab Market

4. LATAM Adalimumab Market Segmentation - by Application
4.1. Introduction
4.2. LATAM Adalimumab Market Revenue, by Application 2013-2023 (US$ Mn)
4.3. LATAM Adalimumab Market Revenue for Rheumatoid Arthritis, 2013-2023, (US$ Mn)
4.4. LATAM Adalimumab Market Revenue for Psoriasis, 2013-2023, (US$ Mn)
4.5. LATAM Adalimumab Market Revenue for Crohn's Disease, 2013-2023, (US$ Mn)
4.6. LATAM Adalimumab Market Revenue for Ulcerative Colitis, 2013-2023, (US$ Mn)
4.7. LATAM Adalimumab Market Revenue for Others, 2013-2023, (US$ Mn)

5. LATAM Adalimumab Market Segmentation - by Country
5.1. Introduction
5.2. LATAM Adalimumab Market Revenue, by Country, 2013-2023 (US$ Mn)
5.3. Brazil Adalimumab Market Revenue, 2013-2023 (US$ Mn)
5.4. Mexico Adalimumab Market Revenue, 2013-2023 (US$ Mn)
5.5. Argentina Adalimumab Market Revenue, 2013-2023 (US$ Mn)
5.6. Colombia Adalimumab Market Revenue, 2013-2023 (US$ Mn)
5.7. Rest of LATAM Adalimumab Market Revenue, 2013-2023 (US$ Mn)

6. Recommendations

7. Company Profiles
7.1. AbbVie, Inc.
7.2. Amgen, Inc.
7.3. Boehringer Ingelheim GmbH
7.4. Eisai Co., Ltd.
7.5. Mylan N.V.
7.6. Novartis AG
7.7. Pfizer, Inc.